A detailed history of Ingalls & Snyder LLC transactions in Omeros Corp stock. As of the latest transaction made, Ingalls & Snyder LLC holds 4,539,415 shares of OMER stock, worth $46.8 Million. This represents 0.7% of its overall portfolio holdings.

Number of Shares
4,539,415
Previous 4,593,148 1.17%
Holding current value
$46.8 Million
Previous $18.6 Million 3.36%
% of portfolio
0.7%
Previous 0.8%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.54 - $5.47 $190,214 - $293,919
-53,733 Reduced 1.17%
4,539,415 $18 Million
Q2 2024

Jul 31, 2024

SELL
$3.04 - $4.23 $319,175 - $444,116
-104,992 Reduced 2.23%
4,593,148 $18.6 Million
Q1 2024

May 13, 2024

BUY
$2.88 - $4.89 $435,968 - $740,238
151,378 Added 3.33%
4,698,140 $16.2 Million
Q4 2023

Jan 29, 2024

SELL
$1.08 - $3.63 $104,569 - $351,471
-96,824 Reduced 2.09%
4,546,762 $14.9 Million
Q3 2023

Nov 02, 2023

SELL
$2.81 - $5.69 $35,616 - $72,120
-12,675 Reduced 0.27%
4,643,586 $13.6 Million
Q2 2023

Jul 27, 2023

SELL
$4.45 - $7.57 $32,396 - $55,109
-7,280 Reduced 0.16%
4,656,261 $25.3 Million
Q1 2023

May 09, 2023

BUY
$2.48 - $5.22 $2.42 Million - $5.1 Million
976,800 Added 26.49%
4,663,541 $21.7 Million
Q4 2022

Jan 31, 2023

SELL
$1.75 - $3.96 $708,510 - $1.6 Million
-404,863 Reduced 9.89%
3,686,741 $8.33 Million
Q3 2022

Oct 21, 2022

SELL
$3.09 - $7.46 $182,798 - $441,318
-59,158 Reduced 1.43%
4,091,604 $12.9 Million
Q2 2022

Aug 11, 2022

SELL
$1.92 - $6.28 $104,309 - $341,179
-54,328 Reduced 1.29%
4,150,762 $11.4 Million
Q1 2022

May 09, 2022

SELL
$5.07 - $7.2 $598,954 - $850,586
-118,137 Reduced 2.73%
4,205,090 $25.3 Million
Q4 2021

Feb 11, 2022

SELL
$5.67 - $8.54 $789,774 - $1.19 Million
-139,290 Reduced 3.12%
4,323,227 $27.8 Million
Q3 2021

Oct 27, 2021

SELL
$13.4 - $16.3 $94,470 - $114,915
-7,050 Reduced 0.16%
4,462,517 $61.5 Million
Q2 2021

Aug 03, 2021

BUY
$14.81 - $19.13 $2.22 Million - $2.87 Million
149,775 Added 3.47%
4,469,567 $66.3 Million
Q1 2021

Apr 21, 2021

SELL
$14.52 - $23.53 $674,178 - $1.09 Million
-46,431 Reduced 1.06%
4,319,792 $76.9 Million
Q4 2020

Jan 27, 2021

SELL
$10.14 - $15.19 $473,588 - $709,448
-46,705 Reduced 1.06%
4,366,223 $62.4 Million
Q3 2020

Oct 21, 2020

SELL
$9.57 - $21.32 $235,804 - $525,324
-24,640 Reduced 0.56%
4,412,928 $44.6 Million
Q2 2020

Jul 31, 2020

SELL
$12.21 - $16.99 $2.43 Million - $3.38 Million
-198,737 Reduced 4.29%
4,437,568 $65.3 Million
Q1 2020

Apr 22, 2020

SELL
$9.03 - $19.72 $129,128 - $281,996
-14,300 Reduced 0.31%
4,636,305 $62 Million
Q4 2019

Jan 15, 2020

SELL
$13.01 - $17.15 $4.85 Million - $6.4 Million
-373,150 Reduced 7.43%
4,650,605 $65.5 Million
Q3 2019

Oct 16, 2019

BUY
$14.55 - $20.56 $846,780 - $1.2 Million
58,198 Added 1.17%
5,023,755 $82 Million
Q2 2019

Jul 11, 2019

SELL
$15.0 - $19.62 $1.68 Million - $2.19 Million
-111,700 Reduced 2.2%
4,965,557 $77.9 Million
Q1 2019

Apr 11, 2019

SELL
$11.65 - $17.72 $1.09 Million - $1.65 Million
-93,150 Reduced 1.8%
5,077,257 $88.2 Million
Q4 2018

Jan 24, 2019

SELL
$10.72 - $16.73 $991,921 - $1.55 Million
-92,530 Reduced 1.76%
5,170,407 $57.6 Million
Q3 2018

Oct 24, 2018

SELL
$17.73 - $26.69 $6.22 Million - $9.36 Million
-350,550 Reduced 6.24%
5,262,937 $128 Million
Q2 2018

Aug 10, 2018

BUY
$10.79 - $24.44 $762,043 - $1.73 Million
70,625 Added 1.27%
5,613,487 $102 Million
Q1 2018

Apr 17, 2018

BUY
$9.0 - $20.16 $1.87 Million - $4.19 Million
207,623 Added 3.89%
5,542,862 $61.9 Million
Q4 2017

Jan 19, 2018

BUY
$13.26 - $22.86 $2.31 Million - $3.98 Million
174,204 Added 3.38%
5,335,239 $104 Million
Q3 2017

Oct 20, 2017

BUY
$19.76 - $24.9 $102 Million - $129 Million
5,161,035
5,161,035 $112 Million

Others Institutions Holding OMER

About OMEROS CORP


  • Ticker OMER
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,730,000
  • Market Cap $647M
  • Description
  • Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical program...
More about OMER
Track This Portfolio

Track Ingalls & Snyder LLC Portfolio

Follow Ingalls & Snyder LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ingalls & Snyder LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ingalls & Snyder LLC with notifications on news.